The protective effects of resveratrol and L-NAME on visceral organs following aortic clamping.
BACKGROUND
This study investigated the effect of temporary occlusion of the aorta on the development of ischemia-reperfusion (I/R) injury of the visceral organs, the optimal timing of administration of resveratrol, and its mechanism of protection via inhibiting nitric oxide (NO) release with an NO synthase inhibitor.


METHODS
Rabbits were divided into seven groups according to the administration period of resveratrol and/or N(G)-nitro-L-arginine methyl ester (L-NAME): control group; group 1, resveratrol during ischemic period; group 2, resveratrol during reperfusion period; group 3, L-NAME during ischemic period; group 4, L-NAME during reperfusion period; group 5, resveratrol during ischemic period and L-NAME during reperfusion period; group 6, L-NAME during ischemic period and resveratrol during reperfusion period. The infrarenal aorta was clamped for 30 min. Blood samples were taken for the biochemical assessment, and organ specimens were taken for pathological assessment at 24hr of reperfusion.


RESULTS
In groups 5 and 6, the renal I/R injury was comparatively milder (I/R injury score 1.04+/-0.29 in control group, 0.25+/-0.17 in group 5, and 0.33+/-0.13 in group 6 [p<0.05]). The I/R injury of bowel was milder in group 5 (I/R injury score 1.8+/-0.80 in control group vs. 0.0+/-0.0 in group 5 [p<0.05]).


CONCLUSIONS
The protective effects of resveratrol on organs that have high metabolic rate like kidney and bowel was proven histopathologically. It may be beneficial to use different pharmacological medications in different periods of the I/R damage as they represent different characteristics with and without oxygen. The combination of resveratrol and L-NAME against I/R injury appears to be an effective option in the near future.
Budak
B
B
Department of Cardiovascular Surgery, Türkiye Yüksek Ihtisas Hospital, Ankara, Turkey.
Seren
M
M
Turan
N N
NN
Sakaogullari
Z
Z
Ulus
A T
AT
D000818:Animals; D001011:Aorta / Q000601:surgery*; D015415:Biomarkers / Q000097:blood; D003250:Constriction; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D007422:Intestines / Q000098:blood supply; D007668:Kidney / Q000098:blood supply; D008099:Liver / Q000098:blood supply; D008168:Lung / Q000098:blood supply; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000517:prevention & control; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage*; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011817:Rabbits; D015427:Reperfusion Injury / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D014781:Viscera / Q000098:blood supply*
D015415:Biomarkers; D004791:Enzyme Inhibitors; D013267:Stilbenes; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D000077185:Resveratrol; D019331:NG-Nitroarginine Methyl Ester